LONDON – Mission Therapeutics Ltd. has raised a hefty £60 million (US$86.3 million) in a third round of funding, as it moves two first-in-class small-molecule inhibitors of the deubiquitylating (DUB) enzymes that are at the heart of DNA damage repair processes, into formal preclinical development.